Description

Miraxol (pramipexole) tablets 0.25 mg. №30

Ingredients

Active ingredient: Pramipexole 0.25 mg per tablet.

Dosage

Dosage: The recommended dose is determined by your healthcare provider. Generally, the starting dose is 0.125 mg three times daily. Dosage may be increased gradually based on individual response.

Indications

Indications: Miraxol tablets are indicated for the treatment of Parkinson’s disease and restless legs syndrome (RLS).

Contraindications

Contraindications: Do not use Miraxol if you are allergic to pramipexole or any other ingredients in the tablets. Consult your doctor before use if you have kidney problems.

Directions

Directions: Take Miraxol tablets exactly as prescribed by your healthcare provider. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence

Pramipexole, the active ingredient in Miraxol tablets, is a dopamine agonist that works by stimulating dopamine receptors in the brain. Studies have shown that pramipexole is effective in improving motor symptoms in patients with Parkinson’s disease and reducing symptoms of restless legs syndrome.

Additional Information

Miraxol tablets should be stored at room temperature away from moisture and heat. Keep this medication out of reach of children. If you experience any severe side effects or allergic reactions, seek medical help immediately.

Pharmacological Effects

Pramipexole acts as an agonist at dopamine D2 and D3 receptors, leading to improved motor function in Parkinson’s disease. It also helps regulate dopamine levels in the brain, which is essential for controlling movement and coordination. Additionally, pramipexole has been shown to alleviate symptoms of restless legs syndrome by modulating dopamine activity in the central nervous system.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of pramipexole in managing symptoms of Parkinson’s disease and restless legs syndrome. In comparison to other dopamine agonists, pramipexole has shown similar effectiveness with a favorable side effect profile. Research suggests that pramipexole may offer better tolerability and sustained efficacy in the long-term treatment of these conditions.

Overall, Miraxol (pramipexole) tablets 0.25 mg. №30 offer a well-established treatment option for Parkinson’s disease and restless legs syndrome, supported by scientific evidence and clinical trials.